Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

被引:104
作者
McKay, Geoffrey A. [1 ]
Beaulieu, Sylvain [1 ]
Arhin, Francis F. [1 ]
Belley, Adam [1 ]
Sarmiento, Ingrid [1 ]
Parr, Thomas, Jr. [1 ]
Moeck, Gregory [1 ]
机构
[1] Targanta Therapeut Inc, St Laurent, PQ H4S 2A1, Canada
关键词
lipoglycopeptide; bactericidal; resistance; IN-VITRO ACTIVITY; POSITIVE BACTERIAL-INFECTIONS; VANCOMYCIN-INTERMEDIATE; ANTIBACTERIAL ACTIVITY; LY333328; GLYCOPEPTIDE; DAPTOMYCIN; STRAINS; COMBINATION; TEICOPLANIN;
D O I
10.1093/jac/dkp126
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Oritavancin, a lipoglycopeptide, possesses bactericidal activity against Gram-positive bacteria including vancomycin-resistant Staphylococcus aureus and enterococci. To understand the time dependence of oritavancin activity, we have undertaken time-kill experiments against isolates of S. aureus, Enterococcus faecalis and Enterococcus faecium, including recent antibiotic-resistant strains. Six strains of S. aureus [methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA)] and five strains of enterococci [vancomycin-susceptible enterococci (VSE) and vancomycin-resistant enterococci (VRE; both VanA and VanB)] were tested in time-kill assays; oritavancin assays included 0.002% polysorbate-80 to ensure quantitative drug recovery. Oritavancin and comparators vancomycin, teicoplanin, linezolid and daptomycin were tested at static concentrations approximating their free peak (fC(max)) and free trough (fC(min)) in plasma when administered at standard doses for complicated skin and skin structure infections. Oritavancin showed concentration-dependent killing of all strains tested: at its fC(max) predicted from a 200 mg dose in humans, oritavancin exerted bactericidal activity (>= 3 log kill relative to starting inoculum) against MSSA, MRSA and VRSA within 1 h and against VSE between 11 and 24 h. At predicted fC(max) from an 800 mg dose, oritavancin was bactericidal against VISA strains at 24 h and against VRE at 10 h. Oritavancin displayed concentration-dependent killing of MSSA, MRSA, VRSA, VISA, VSE and VRE. Oritavancin was more rapidly bactericidal against all strains tested than were vancomycin, teicoplanin, linezolid or daptomycin at physiologically relevant concentrations. These data support the conclusion that oritavancin exerts concentration-dependent bactericidal activity on recent, drug-resistant isolates of S. aureus and enterococci.
引用
收藏
页码:1191 / 1199
页数:9
相关论文
共 50 条
[1]   Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459
[2]  
[Anonymous], 1999, M26A NAT COMM CLIN L
[3]  
[Anonymous], 2012, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard
[4]   Effect of polysorbate 80 on oritavancin binding to plastic surfaces: Implications for susceptibility testing [J].
Arhin, Francis F. ;
Sarmiento, Ingrid ;
Belley, Adam ;
McKay, Geoffrey A. ;
Draghi, Deborah C. ;
Grover, Parveen ;
Sahm, Daniel F. ;
Parr, Thomas R., Jr. ;
Moeck, Gregory .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (05) :1597-1603
[5]   Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities [J].
Babalola, CP ;
Patel, KB ;
Nightingale, CH ;
Nicolau, DP .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (04) :343-348
[6]   Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium [J].
Baltch, AL ;
Smith, RP ;
Ritz, WJ ;
Bopp, LH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2564-2568
[7]   Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus [J].
Belley, Adam ;
Neesham-Grenon, Eve ;
Arhin, Francis F. ;
Mckay, Geoffrey A. ;
Parr, Thomas R., Jr. ;
Moeck, Gregory .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (10) :3820-3822
[8]   In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide [J].
Biavasco, F ;
Vignaroli, C ;
Lupidi, R ;
Manso, E ;
Facinelli, B ;
Varaldo, PE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2165-2172
[9]   Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004) [J].
Biedenbacha, Douglas J. ;
Bellb, Jan M. ;
Sadera, Helio S. ;
Fritsche, Thomas R. ;
Jones, Ronald N. ;
Turnidge, John D. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (02) :143-149
[10]   Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection [J].
Boylan, CJ ;
Campanale, K ;
Iversen, PW ;
Phillips, DL ;
Zeckel, ML ;
Parr, TR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1700-1706